PharmaCyte Biotech Inc (PMCB)

[DragonBear]

PharmaCyte’s Clinical Trial in Pancreatic Cancer-all PMCB nonsense

What makes this cell encapsulation different than others that have been tried?

It will fail. Unlike past nano-encapsulation of chemo drugs.

None of the others can effectively freeze live cells

Nothing new. Liquid N2 transport dates back to the 1950s. It has widespread usage.

Why would there be so much interest in a “targeted chemotherapy” treatment with little to no treatment-related side effects

As in imaginary interest by the market? Why did Austrianova go BK in 2003 while trying to obtain funding? Ifosfamide is an extremely toxic chemo drug.

developing treatments for other solid cancerous tumors and diabetes are far more lucrative

Especially when they are based on the cutting edge of science, and work. As opposed to a 20 yr old chemotherapy.

that has proven itself effective and safe to use in past clinical trials

Ad hoc studies 20 yrs ago, not sanction by the FDA. Faulty in structure. Where was the comparison arm of Metronomic Ifosfamide+CIABs vs Metronomic Ifosfamide alone? There's no proof the presence of CIABs does anything.

and it could significantly reduce tumor size

"Could"? "Significantly"? What do those past PR pump words mean. CT results are not based on words. They are based on measurable metrics. But in Kenny's world we are back to the Kenny Fable of: AS little dab will doo ya! Just treat with a little Ifosfamide, and the tumor melts away. So why hasn't Metronomic Ifosfamide been used in 1st line patients?

Chemotherapy with little to no side effects is unheard of

Also unheard of is any claim that Ifosfamide at 1.2 gms/m2 is not toxic. PMCB proposing a dose of 1 gm/m2. Not a major difference is it? There will be side effects. Including severe bone marrow suppression, and all the problems that presents for 2nd line patients.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form

And how much is converted in humans, by the magic CIABs, as opposed by the liver? Where's the data?

Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at about one-third the normal dose.

It still will be activated in the liver. Oooh 1/3 the usual dose. Well, then how about Glufosfamide, the latest analog of Ifosfamide, which has 1/4 the toxicity of Ifosfamide. And it doesn't need any magic cells to convert it. It goes in by active transport (via passive diffusion for Ifosfamide), and gets converted inside the cancer cell to its active form. Not only that it's active under hypoxic conditions, where Ifosfamide is not. Glufosfamide is currently in Phase 3 CT testing for 2nd line patients.

if the data produced in a planned clinical trial from PharmaCyte’s therapy are significantly better than the data from the comparator arm(s), this may allow PharmaCyte to apply to the FDA for accelerated approval.

Another Kenny dream for the SHs. Ifosfamide has already failed in prior CTs involving 2nd line PC patients. It will continue to fail.

And once again the challenge to Kenny:

Provide the link(s) of published journal papers which indicates Metronomic Ifosfamide can readily diffuse through the more dense and developed stromal structure of the PC tumor in a 2nd line PC patient. Where it can overcome the high interstitial pressure , of a collapsing vascular structure (analogous to swimming upstream against a strong current), and degradation of the drug by stromal enzymes. Also find links that demonstrate a small amount of Ifosfamide that gets through, can damage quiescent cancer cells found in a hypoxic environment.

Numbers don’t lie and as of 2016, $827-billion are spent annually in the treatment of diabetes worldwide

Also not a lie is Kenny is inferring false claims about PMCB having a diabetes treatment. How much insulin does empty cellulose beads produce? Where is the competition currently? Answer: Further along than PMCB ever will be. The real solution for diabetes Type 1 won't be encapsulated cells. It will be what two companies are working on - a MHC-1 knockout islet cell expressing PD-L1. The host immune cells will ignore them, as the islet cells repopulate the pancreas. No doubt others are working on like solutions.

but let’s be honest—it is the company’s live-cell encapsulation technology that is truly on trial in the court of public opinion

Let's be more honest... no one cares about a 20 yr old back water antiquated chemotherapy concept. Technology??? LOL Yeah, really high tech, compared to a bispecific T-CAR Abs, or a CCL5/CCR5 antagonist treatment combined with the anti-PD-L1. That's right... the so called PMCB "technology" is primitive in comparison. That is what Kenny is peddling.